A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular Clinical Trial

Official title:

A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02564614
• Other study ID #: NP29700
• Status: Completed
• Phase: Phase 1
• First received: September 28, 2015
• Last updated: February 13, 2018
• Start date: May 2, 2016
• Est. completion date: January 22, 2018

Study information

• Verified date: February 2018
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open-label study will demonstrate proof-of-mechanism of HIF1A inhibition by a decrease of HIF1A mRNA after intravenous (IV) infusion of RO7070179 in participants with hepatocellular carcinoma (HCC) who have failed at least one line of systemic therapy. This will be a single arm study and all participants will receive RO7070179, 13 milligram per kilogram per week (mg/kg/week), 2-hour IV infusion on Days 1 and 4 during Week 1 of Cycle 1, followed by once weekly in 6 week cycle. Treatment with RO7070179 will be continued until disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: January 22, 2018
• Est. primary completion date: January 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female of >=18 years of age with the Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Child-Pugh score of 5-7, and Life expectancy of 3 months or greater.

• Confirmed to have HCC as described by the American Association for the Study of Liver Disease (AASLD).

• Participants who have failed at least one line of systemic therapy for advanced stage HCC or participants who are ineligible or unable to tolerate the standard of care treatment.

• Have measurable or evaluable disease.

• Participants with normal major organ functions as defined by hemoglobin (HgB) >= 8.5 gram/decilitre (dL), absolute neutrophil count (ANC) >= 1000/microliter (mcL), platelet >= 60,000/micL, aspartate aminotransferase/alanine transaminase (AST/ALT) <= 3 x Upper Limit of Normal (ULN), total Bilirubin <= 2 x ULN, creatinine <= 2 x ULN.

• Willingness to undergo two tumor biopsies: before and after administration of RO7070179.

Exclusion Criteria:

• Concurrent serious medical illness that could potentially interfere with protocol compliance (such medical illness will not include hepatitis or cirrhosis, as the degree of liver impairment caused by these diseases are covered by other exclusion criteria).

• Active hepatitis B or C, but participants on stable medications for hepatitis B or C.

• Bleeding esophageal or gastric varices within 2 months before enrollment.

• Participants who need to take therapeutic anti-coagulation or anti-platelet therapy.

• Presence of ascites that preclude biopsy of liver lesions.

• History of unstable angina or myocardial infarction within 12 months prior to Day 1 or ischemic heart disease.

• Known HIV positive and positive screening pregnancy test or is breast-feeding.

• Female or male of reproductive capacity unwilling to use methods of contraception to prevent pregnancy during this study. Participants unwilling to use methods of contraception to prevent pregnancy for 6 months after the last dose of RO7070179 due to the potential for prolonged half-life of RO7070179 in the liver.

• Known, clinically suspected, or history of CNS tumor involvement.

• Prior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat HCC within 4 weeks before the first scheduled administration of RO7070179.

• Participants who have not recovered from any reversible side effects (except alopecia) to Grade 0 or 1 toxicity attributed to the administration of an investigational therapeutic agent, chemotherapy, immunotherapy, radiotherapy, or other agents previously used to treat the cancer.

• Any condition that, in the opinion of the investigator or the Sponsor, makes the patients unsuitable for the study.

• Inability to comply with the study protocol.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hypoxia

Intervention

Drug:
• RO7070179
RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.

Locations

Country	Name	City	State
United States	Gabrail Cancer Center	Canton	Ohio
United States	Ohio State University	Columbus	Ohio
United States	Indiana University	Indianapolis	Indiana
United States	Columbia University Medical Center	New York	New York
United States	Laura and ISAAC Perlmutter Cancer Center at NYU Langone.	New York	New York
United States	NYU Langone Medical Center; Bellevue Hospital	New York	New York
United States	Weill Cornell Medical College	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in hypoxia-inducible factor 1a (HIF1A) Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in HIF2 Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in Vascular Endothelial Growth Factor (VEGF) Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in Erythropoietin (EPO) Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in Prolyl 4 Hydroxylase Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change From Baseline to Week 6 in CD34/von Willebrand factor (VWF) Tumor Concentrations		Pre-dose (baseline) and Week 6
Secondary	Change in Blood Alpha-fetoprotein (AFP) Concentrations from Baseline		Week 1 and Week 4 for Cycle 1 and at Week 1 for subsequent treatment cycles
Secondary	Time to Progression (TTP) According to Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST)		Every 12 weeks upto 24 Months
Secondary	Percentage of Participants With Complete Response (CR) and Partial Response (PR) According to RECIST and mRECIST		Every 12 weeks upto 24 Months
Secondary	Duration of Response (DOR) According to RECIST and mRECIST		Every 12 weeks upto 24 Months
Secondary	Progression Free Survival (PFS) According to RECIST and mRECIST		Every 12 weeks upto 24 Months
Secondary	Overall Survival (OS) According to RECIST and mRECIST		Every 12 weeks upto 24 Months
Secondary	Percentage of Participants With Tumor Growth According to RECIST and mRECIST		Every 12 weeks upto 24 Months
Secondary	Maximum Observed Plasma Concentration (Cmax)		pre- and post-dose at Week 1, Week 6
Secondary	Time to Reach Maximum Observed Plasma Concentration (Tmax)		pre- and post-dose at Week 1, Week 6
Secondary	Area under the Concentration-Time Curve From Zero to 168 Hours [AUC (0-168 hours)]		pre- and post-dose at Week 1, Week 6
Secondary	Plasma Decay Half-Life (t1/2)		pre- and post-dose at Week 1, Week 6